Study Says Meridia May Up Risk Of Heart Attack, Stroke

By Jessica Dye

Law360, New York (September 02, 2010, 11:15 AM ET) -- A study published Thursday in The New England Journal of Medicine warned that Abbott Laboratories’ weight-loss drug Meridia may increase the risk of nonfatal heart attack and stroke in some users, raising new concerns about the controversial pill just weeks before a U.S. advisory panel is set to consider its fate.

The Abbott-funded study found that Meridia — the brand name for sibutramine hydrochloride — could increase the chances of nonfatal heart attacks and strokes in obese users over the age of 55 years with preexisting...
To view the full article, take a free trial now.

Already a subscriber? Click here to login

You must correct or enter the following before you can submit this form:

All fields required

  5. Required

Only Law360 gives you:

Non-stop coverage of high-stakes litigation across 30 practices

Real-time tracking and reports on 10,000+ companies, firms and industries

Over 80,000 attorney profiles with neutral data collected from active lawsuits

Research tools to find cases, court documents, attorneys and companies

Customized feeds and alerts that can easily be shared with colleagues

In-depth expert analysis from high-profile attorneys at top firms

Access to our vault with over 75,000 original articles